Nomura keeps INR 1,740 target for Dr Reddy stock

Published on 10/22/2026 at 09:32 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Nomura sees an 18.10 percent margin for the second quarter versus 14.30 percent in the first. Results for Dr Reddy stock are due October 23, 2026.

Nomura and results dates

Nomura kept its INR 1,740 target on October 22, 2026, while projecting 30.00 percent earnings upside.
Revenue reached INR 80.71 billion and net income INR 4.435 billion in the first quarter of fiscal 2027.
The second-quarter and first-half 2027 results and the earnings call are scheduled for October 23, 2026.

Dr Reddy stock, pharmaceuticals, Nomura target, earnings, NSE, Illustration mit AI erstellt.

Dr Reddy's Laboratories stock stood at INR 1,231.70 on the NSE on October 22, 2026 at 12:59 p.m. IST, while Moneycontrol reported that Nomura kept its Buy rating and INR 1,740 target that day. The brokerage expects second-quarter operating gains ahead of the results scheduled for October 23, 2026.

Three target-setting milestones

On July 23, 2026, Dr Reddy reported first-quarter fiscal 2027 revenue of INR 80.71 billion and net income of INR 4.435 billion, according to Economic Times. On September 29, 2026, Citi raised its target from INR 1,040 to INR 1,450, as reported by Cerbat Gem. On October 22, 2026, Nomura kept its INR 1,740 target and projected 30.00 percent earnings upside, according to Moneycontrol.

What does the 18.10 percent margin imply?

Nomura forecasts an adjusted EBITDA margin of 18.10 percent for the second quarter, versus 14.30 percent in the first quarter of fiscal 2027. Its sales, EBITDA and profit-after-tax estimates are 1.40 percent, 23.10 percent and 20.70 percent above consensus, respectively, according to Moneycontrol. The analysis also says commercial semaglutide supplies are expected to resume in November 2026, while a potential biosimilar abatacept approval has a December 18, 2026 target action date.

Two October 23 company dates

The next company dates are October 23, 2026, for second-quarter and first-half 2027 results covering the period ended September 30, 2026, and October 23, 2026, at 10:00 a.m. ET for the earnings call. The schedule was disclosed in a company filing carried by StockTitan.

NSE valuation and operating risk

At INR 1,231.70 on October 22, 2026, the NSE quote stood between its INR 1,101.00 52-week low and INR 1,414.90 52-week high. The latest reported market capitalization was INR 1.0 trillion, while the first-quarter cash flow from operations was negative INR 927.00 million for the period ended June 30, 2026.